Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy

Authors: Annamaria Ruzzo, Vincenzo Catalano, Emanuele Canestrari, Elisa Giacomini, Daniele Santini, Giuseppe Tonini, Bruno Vincenzi, Giammaria Fiorentini, Mauro Magnani, Francesco Graziano

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstracts

Background

IL-6 triggers oncogenic/angiogenic signals and the cytokine-dependent pro-cachexia cascade. The prognostic role of the functional IL-6 (promoter) rs1800795 and the IL-6R (receptor) rs8192284 single nucleotide polymorphisms (SNP) was studied in patients with advanced gastric cancer treated with palliative chemotherapy.

Methods

One-hundred-sixty-one patients were genotyped for rs1800795 and rs8192284 SNPs using polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) analysis assay. These results were studied for association with overall survival (OS).

Results

In 161 assessable patients, frequencies of rs1800795 G/G, G/C and C/C genotypes were 46%, 42% and 12%, respectively. Frequencies of rs8192284 A/A, A/C and C/C genotypes were 36%, 45% and 19%, respectively. Carriers of the rs1800795 G/G and rs8192284 C/C genotypes showed the worst OS. In the multivariate model, rs1800795 G/G (1.69 hazard ratio; 95% confidence interval 1.18-2.42), and rs8192284 C/C (1.78 hazard ratio; 95% confidence interval 1.12-2.83) confirmed an adverse prognostic impact.

Conclusions

In this population, genetic variants that up-regulate the IL-6 system showed impact on OS. This findings sustain the hypothesis that anti-IL-6 compounds deserve clinical studies as novel therapeutics in the palliative treatment of cancer patients.
Appendix
Available only for authorised users
Literature
1.
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S: The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 1813, 2011: 878-888.
2.
Rose-John S: IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012, 8: 1237-1247. 10.7150/ijbs.4989.CrossRefPubMedPubMedCentral
3.
Tanaka T, Kishimoto T: Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci. 2012, 8: 1227-1236. 10.7150/ijbs.4666.CrossRefPubMedPubMedCentral
4.
Guo Y, Xu F, Lu T, Duan Z, Zhang Z: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012, 38: 904-910. 10.1016/j.ctrv.2012.04.007.CrossRefPubMed
5.
Sansone P, Bromberg J: Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012, 30: 1005-1014. 10.1200/JCO.2010.31.8907.CrossRefPubMedPubMedCentral
6.
Fearon KC, Glass DJ, Guttridge DC: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16: 153-166. 10.1016/j.cmet.2012.06.011.CrossRefPubMed
7.
Kinoshita H, Hirata Y, Nakagawa H, Sakamoto K, Hayakawa Y, Takahashi R, Nakata W, Sakitani K, Serizawa T, Hikiba Y, Akanuma M, Shibata W, Maeda S, Koike K: Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. PLoS One. 2013, 8: e60914-10.1371/journal.pone.0060914.CrossRefPubMedPubMedCentral
8.
Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K: Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br J Cancer. 2011, 105: 407-412. 10.1038/bjc.2011.246.CrossRefPubMedPubMedCentral
9.
Mejías-Luque R, Peiró S, Vincent A, Van Seuningen I, de Bolós C: IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta. 2008, 1783: 1728-1736. 10.1016/j.bbamcr.2008.05.020.CrossRefPubMed
10.
Jackson CB, Judd LM, Menheniott TR, Kronborg I, Dow C, Yeomans ND, Jackson CB, Judd LM, Menheniott TR, Kronborg I, Dow C, Yeomans ND, Boussioutas A, Robb L, Giraud AS: Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. J Pathol. 2007, 213: 140-151. 10.1002/path.2218.CrossRefPubMed
11.
Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM, Kuo ML: IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer. 2007, 120: 2600-2608. 10.1002/ijc.22599.CrossRefPubMed
12.
Howlett M, Judd LM, Jenkins B, La Gruta NL, Grail D, Ernst M, Giraud AS: Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. Gastroenterology. 2005, 129: 1005-1018. 10.1053/j.gastro.2005.06.068.CrossRefPubMed
13.
Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, Lin JT: Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci. 2004, 11: 517-527. 10.1007/BF02256101.CrossRefPubMed
14.
Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML, Lin JT: Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol. 2002, 17: 1165-1169. 10.1046/j.1440-1746.2002.02873.x.CrossRefPubMed
15.
Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim HJ: Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009, 9: 155-10.1186/1471-2407-9-155.CrossRefPubMedPubMedCentral
16.
Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003, 39: 184-191. 10.1016/S0959-8049(02)00596-8.CrossRefPubMed
17.
Smith AJ, Humphries SE: Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 2009, 20: 43-59. 10.1016/j.cytogfr.2008.11.006.CrossRefPubMed
18.
19.
Ferreira RC, Freitag DF, Cutler AJ, Howson JM, Rainbow DB, Smyth DJ, Kaptoge S, Clarke P, Boreham C, Coulson RM, Pekalski ML, Chen WM, Onengut-Gumuscu S, Rich SS, Butterworth AS, Malarstig A, Danesh J, Todd JA: Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 2013, 9: e1003444-10.1371/journal.pgen.1003444.CrossRefPubMedPubMedCentral
20.
Lippitz BE: Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013, 14: e218-28. 10.1016/S1470-2045(12)70582-X.CrossRefPubMed
21.
Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G: Second -line chemotherapy for patients with advanced gastric cancer: who may benefit?. Br J Cancer. 2008, 99: 1402-1407. 10.1038/sj.bjc.6604732.CrossRefPubMedPubMedCentral
22.
Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH: IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011, 71: 424-434. 10.1158/0008-5472.CAN-10-1496.CrossRefPubMed
23.
Waetzig GH, Rose-John S: Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets. 2012, 16: 225-236. 10.1517/14728222.2012.660307.CrossRefPubMed
24.
Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Høyer-Hansen G, Eefsen RL, Reynolds AR, Brodt P: The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 2013, 73: 2031-2043. 10.1158/0008-5472.CAN-12-3931.CrossRefPubMed
25.
Li S, Wang N, Brodt P: Metastatic cells can escape the proapoptotic effects of TNF-α through increased autocrine IL-6/STAT3 signaling. Cancer Res. 2012, 72: 865-875. 10.1158/0008-5472.CAN-11-1357.CrossRefPubMed
26.
Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S, Aoki T: Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer. 2005, 8: 124-131. 10.1007/s10120-005-0315-x.CrossRefPubMed
27.
Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, Beckmann MW, Zeillinger R, Koelbl H, Tempfer CB: An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003, 63: 3066-3068.PubMed
28.
DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B: Interleukin-6-174G- > C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 2003, 63: 8051-8056.PubMed
29.
DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS: Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res. 2009, 69: 4184-4191. 10.1158/0008-5472.CAN-08-2989.CrossRefPubMedPubMedCentral
30.
Lagmay JP, London WB, Gross TG, Termuhlen A, Sullivan N, Axel A, Mundy B, Ranalli M, Canner J, McGrady P, Hall B: Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res. 2009, 15: 5234-5239. 10.1158/1078-0432.CCR-08-2953.CrossRefPubMedPubMedCentral
31.
Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D’Alo’ F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G: Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol. 2007, 18: 1376-1381. 10.1093/annonc/mdm132.CrossRefPubMed
32.
Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, Huang YJ, Wu MS: Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res. 2008, 14: 428-434. 10.1158/1078-0432.CCR-07-1032.CrossRefPubMed
33.
Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD: An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood. 2012, 119: 503-512. 10.1182/blood-2011-07-367052.CrossRefPubMedPubMedCentral
34.
Knüpfer H, Preiss R: sIL-6R: more than an agonist?. Immunol Cell Biol. 2008, 86: 87-91. 10.1038/sj.icb.7100113.CrossRefPubMed
35.
Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV: Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012, 13: 827-837. 10.1016/S1470-2045(12)70241-3.CrossRefPubMed
36.
Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, Chung S, Luther T, Paholak HJ, Liu S, Hassan KA, Zen Q, Clouthier SG, Wicha MS: Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012, 47: 570-584. 10.1016/j.molcel.2012.06.014.CrossRefPubMedPubMedCentral
37.
Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM: Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009, 28: 2940-2947. 10.1038/onc.2009.180.CrossRefPubMed
38.
Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M: Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer. 2009, 115: 5541-5549. 10.1002/cncr.24597.CrossRefPubMedPubMedCentral
39.
Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, Takahashi K: Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2013, 31: e69-72. 10.1200/JCO.2012.44.2020.CrossRefPubMed
40.
Hirata H, Tetsumoto S, Kijima T, Kida H, Kumagai T, Takahashi R, Otani Y, Inoue K, Kuhara H, Shimada K, Nagatomo I, Takeda Y, Goya S, Yoshizaki K, Kawase I, Tachibana I, Kishimoto T, Kumanogoh A: Favorable Responses to Tocilizumab in Two Patients With Cancer-Related Cachexia. J Pain Symptom Manage. 2013, 46: e9-e13. 10.1016/j.jpainsymman.2013.01.009.CrossRefPubMed
41.
Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F: A Phase I, Open-Label Study of Siltuximab, anAnti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clin Cancer Res. 2013, 19: 3659-3670. 10.1158/1078-0432.CCR-12-3349.CrossRefPubMed
42.
Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M: A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 2013, 31: 669-676. 10.1007/s10637-012-9857-z.CrossRefPubMed
43.
Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011, 11: 1663-1668. 10.1517/14712598.2011.627850.CrossRefPubMed
Metadata
Title
Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy
Authors
Annamaria Ruzzo
Vincenzo Catalano
Emanuele Canestrari
Elisa Giacomini
Daniele Santini
Giuseppe Tonini
Bruno Vincenzi
Giammaria Fiorentini
Mauro Magnani
Francesco Graziano
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-357

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells

Research article

Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy

Research article

Immunotherapy of hepatocellular carcinoma with small double-stranded RNA

Research article

Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis

Research article

Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis

Research article

A computational model to predict bone metastasis in breast cancer by integrating the dysregulated pathways
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits